PMID- 36328248
OWN - NLM
STAT- MEDLINE
DCOM- 20221129
LR  - 20221206
IS  - 1878-5492 (Electronic)
IS  - 0966-3274 (Linking)
VI  - 75
DP  - 2022 Dec
TI  - Symptomatic atherosclerotic vascular disease and graft survival in primary kidney 
      transplant recipients - Observational analysis of the united network of organ 
      sharing database.
PG  - 101734
LID - S0966-3274(22)00208-8 [pii]
LID - 10.1016/j.trim.2022.101734 [doi]
AB  - OBJECTIVES: The aim of this study was to investigate whether symptomatic 
      atherosclerotic vascular disease (SAVD) was associated with graft survival in 
      primary kidney transplant recipients. SUMMARY BACKGROUND DATA: Recipient 
      atherosclerotic vascular disease is associated with increased mortality rates 
      amongst renal transplant patients. However, its relationship with graft survival 
      has not been well studied. METHODS: This retrospective observational analysis was 
      performed using data for adult kidney transplant recipients between 11/09/2000 
      and 28/02/2020 extracted from the UNOS national organ transplantation database. 
      Patients were divided into two groups based on recipient history of symptomatic 
      atherosclerotic disease (angina or peripheral vascular disease). Risk-adjusted 
      outcomes were assessed by multivariate Cox regression analysis adjusting for both 
      donor and recipient characteristics. RESULTS: 11,771 adult kidney transplant 
      recipients from the UNOS database were eligible for analysis (1543 had a history 
      of SAVD, 10,228 did not have a history of SAVD). After adjusting for confounders, 
      positive SAVD status was associated with an adverse effect on graft survival at 
      both 1 year (HR 1.35, p < 0.001) and 10 years (HR 1.15, p < 0.001). CONCLUSIONS: 
      SAVD should be considered an independent risk factor for poor prognosis in 
      patients undergoing kidney transplant.
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Otunla, Afolarin A
AU  - Otunla AA
AD  - Medical Sciences Division, University of Oxford, Oxford, UK. Electronic address: 
      Afolarin.Otunla@gtc.ox.ac.uk.
FAU - Shanmugarajah, Kumaran
AU  - Shanmugarajah K
AD  - Department of Surgery, University of Chicago, Chicago, IL, USA.
FAU - Salciccioli, Justin D
AU  - Salciccioli JD
AD  - Department of Medicine, Mount Auburn Hospital, Cambridge, MA, USA; Harvard 
      Medical School, Boston, MA, USA.
FAU - Marshall, Dominic C
AU  - Marshall DC
AD  - British Heart Foundation Centre of Excellence, King's College London, London, UK.
FAU - Davies, Alun H
AU  - Davies AH
AD  - Section of Vascular Surgery, Department of Surgery & Cancer, Imperial College 
      London, UK; Imperial Vascular Unit, Imperial College Healthcare NHS Trust, 
      London, UK.
FAU - Madariaga, Maria Lucia
AU  - Madariaga ML
AD  - Department of Surgery, University of Chicago, Chicago, IL, USA.
FAU - Shalhoub, Joseph
AU  - Shalhoub J
AD  - Section of Vascular Surgery, Department of Surgery & Cancer, Imperial College 
      London, UK; Imperial Vascular Unit, Imperial College Healthcare NHS Trust, 
      London, UK.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20221031
PL  - Netherlands
TA  - Transpl Immunol
JT  - Transplant immunology
JID - 9309923
SB  - IM
MH  - Adult
MH  - Humans
MH  - Graft Survival
MH  - *Kidney Transplantation
MH  - *Tissue and Organ Procurement
MH  - Retrospective Studies
MH  - Transplant Recipients
MH  - *Vascular Diseases
MH  - Graft Rejection/epidemiology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Atherosclerosis
OT  - Graft survival
OT  - Kidney transplantation
OT  - Prognostication
OT  - Rejection
EDAT- 2022/11/04 06:00
MHDA- 2022/11/30 06:00
CRDT- 2022/11/03 20:33
PHST- 2022/09/07 00:00 [received]
PHST- 2022/10/27 00:00 [accepted]
PHST- 2022/11/04 06:00 [pubmed]
PHST- 2022/11/30 06:00 [medline]
PHST- 2022/11/03 20:33 [entrez]
AID - S0966-3274(22)00208-8 [pii]
AID - 10.1016/j.trim.2022.101734 [doi]
PST - ppublish
SO  - Transpl Immunol. 2022 Dec;75:101734. doi: 10.1016/j.trim.2022.101734. Epub 2022 
      Oct 31.